GSK India Builds Momentum With Innovative Portfolio, Reports Continued Profitable Growth For Year Ended 31st March 2026
The Company’s Board of Directors recommend final dividend of Rs. 57 per equity share for the year ended 31st March 2026
Mumbai: GlaxoSmithKline Pharmaceuticals Ltd (GSK India) today announced its financial results for the fourth quarter and full year ended 31st March 2026. The Company continued its trajectory of profitable growth and margin expansion. This performance was driven by pricing measures, focused investments in innovative therapies, improved field force productivity, AI-led optimisation and disciplined cost management.
The Company reported full year revenue of INR 3790 crores, a growth of 2%. Profit After Tax (PAT) increased by 10% to INR 1012 crores, while EBITDA margins expanded by 290 basis points (bps) to 34%.
For the quarter ending 31st March 2026, the Company reported revenue of INR 989 crores and PAT of INR 275 crores while EBITDA margins improved by 90 bps to 35%.
As reported previously, supply chain disruptions during the year constrained the availability of certain key products leading to a material impact on topline growth. These challenges have accelerated the Company’s efforts to strengthen supply chain resilience through enhanced contingency planning, diversified sourcing and improved end-to-end visibility to ensure business continuity.
Portfolio Performance Highlights
The General Medicines portfolio delivered competitive performance during the quarter, with the top 4 promoted brands growing ahead of the market (EI* >100; Source: IQVIA). Key promoted brands such as Augmentin, Calpol and T-Bact continued to reinforce their leadership positions in their respective categories while the tail-end distributed portfolio saw significant headwinds.
The Vaccines business grew on strong demand and continued leadership in the self-pay private paediatric vaccines market. Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted) achieved critical mass as increasing awareness of preventive healthcare and adult immunisation translated into positive outcomes from in-clinic conversations.
The Oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), is tracking strongly. A key milestone this year was Jemperli’s first-line approval by Indian regulators for primary advanced and recurrent endometrial cancer, leading to a significant expansion of the eligible patient population. This has laid the foundations for patient-centric and sustainable growth in Oncology.
Commenting on the full-year results, Mr. Bhushan Akshikar, Managing Director, GSK India, said: “The strong delivery of our Oncology portfolio signals a key inflection point in GSK India’s journey to evolve into an innovation-led company, focused on areas of high unmet medical need. Our progress is underpinned by scientific rigour, disciplined execution and an unwavering commitment to our patients in India. Building on this momentum, we will continue to invest in innovative, high-growth therapy areas to make a positive impact at scale. Our ambition is driven by a sharp focus on topline growth and sustainable profitability.”
The Company has received marketing authorisation in India for Blenrep (belantamab mafodotin), an anti-BCMA ADC** therapy indicated for relapsed or refractory multiple myeloma in adults. Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases a year.1 Launch plans will be announced at an appropriate time.
About GSK India
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together. For more information, visit www.gsk-india.com.
Media Contacts
Communications and Government Affairs
Carson Dalton - carson.a.dalton@gsk.com
Farah Bookwala - farah.a.bookwala@gsk.com
1Pg 21, GSK Annual Report 2025, gsk.com/media/kn0bknmd/annual-report-2025.pdf
*The Evolution Index (EI) is a metric used to evaluate the performance of a product relative to the overall market growth.
** BCMA: B-cell maturation antigen, ADC: Antibody-drug-conjugates
